Toward clinical translation of carbon nanomaterials in anticancer drug delivery: the need for standardisation

• Michał Bartkowski,
• Francesco Calzaferri and
• Silvia Giordani

Beilstein J. Nanotechnol. 2025, 16, 2092–2104, doi:10.3762/bjnano.16.144

• Michal Bartkowski Francesco Calzaferri Silvia Giordani School of Chemical Sciences, Dublin City University, Glasnevin, Dublin, Ireland Life Science Institute, Dublin City University, Glasnevin, Dublin, Ireland 10.3762/bjnano.16.144 Abstract Carbon nanomaterials (CNMs), including graphene, carbon

• enhancing therapeutic delivery, particularly in areas such as cancer treatment. This perspective highlights critical considerations in the development of CNM-based nanocarriers, spanning from initial design to clinical implementation. Keywords: carbon nanomaterials (CNMs); carbon nanoparticles (CNPs); drug

• nanomaterials (CNMs) have been largely developed as nanocarriers for drug delivery due to their biocompatibility, high surface area, tuneable physicochemical properties, and targeting capabilities [13][14]. However, CNMs also present a subset of challenges, including toxicity concerns, expensive and time

Carbon nano-onions as fluorescent on/off modulated nanoprobes for diagnostics

• Stefania Lettieri,
• Marta d’Amora,
• Adalberto Camisasca,
• Alberto Diaspro and
• Silvia Giordani

Beilstein J. Nanotechnol. 2017, 8, 1878–1888, doi:10.3762/bjnano.8.188

• sensing applications [7], multishell fullerenes, known as carbon nano-onions (CNOs) [8][9], prepared by thermal annealing of detonation nanodiamonds (d-NDs) [10], are an attractive class of carbon nanomaterials (CNMs) for imaging, diagnostic and therapeutic applications, due to their unique properties